INTRODUCTION
============

Gastric cancer remains the second most frequent cause of cancer-related deaths and ranks 4th in cancer incidence worldwide.[@b1-jcp-20-25] In Republic of Korea, gastric cancer is the second most common cancer followed by thyroid cancer and the third cause of cancer-related death followed by lung and liver cancer in the database of 2013.[@b2-jcp-20-25] The prognosis of gastric cancer varies depending on stages. The 5-year survival rates for advanced gastric cancer are less than 20%. On the contrary, early gastric cancer (EGC) makes a good prognosis that the 5-year survival rates are over 90% to 95%.[@b3-jcp-20-25]--[@b5-jcp-20-25] Therefore, it is important to individualize the management for high risk group of gastric cancer. The risk factors of gastric cancer are *Helicobacter pylori* infection, salt intake, smoking, alcohol, family history of gastric cancer, atrophic gastritis (AG), and intestinal metaplasia (IM).[@b6-jcp-20-25] Particularly AG and IM are considered to be premalignant lesions of gastric cancer.[@b6-jcp-20-25] For this reason effective diagnosis and management of AG and IM is a very important research topic to prevent gastric cancer.[@b7-jcp-20-25]--[@b9-jcp-20-25] According to a recent meta-analysis, the incidence rates of AG are in a wide range from 0% to 10.9% per year.[@b10-jcp-20-25] This wide range of incidence of AG could be explained by the different settings in which the diagnoses of AG were made.[@b10-jcp-20-25] *H. pylori* infection is the most important risk factor of AG and IM. AG is considered to be an antecedent to IM.[@b11-jcp-20-25] Thus the risk factors for AG are expected to be similar to those for IM. However, bacterial factors have been found to play an important role for AG while environmental and host factors are more important for IM.[@b11-jcp-20-25] From this background, the aim of this review is to provide comprehensive information regarding the epidemiology, etiology, diagnosis and management of AG and IM, which will lay a foundation to establish strategies to prevent gastric cancer.

ATROPHIC GASTRITIS AND INTESTINAL METAPLASIA AS PRECURSOR LESIONS OF GASTRIC CANCER
===================================================================================

Chronic inflammation can damage inflamed cells and trigger a multistep process of carcinogenesis. In premalignant tissues associated with chronic inflammation, tumor cells and leukocytes of various kinds such as neutrophils, macrophages, monocytes, mast cells, eosinophils, dendritic cells, and lymphocytes are present.[@b12-jcp-20-25],[@b13-jcp-20-25] These inflammatory cells contribute to cancer initiation, promotion and metastasis by producing cytokines, reactive oxygen species, and reactive nitrogen species. Various oxidant products can damage cellular DNA, RNA, and proteins by chemical reactions such as oxidation, nitration, nitrosation, and halogenation. Damages of cellular components result in increased mutations and altered functions of important enzymes and proteins in premalignant tissues, so contributing to the multistage carcinogenesis process.[@b14-jcp-20-25] According to the Correa model, chronic inflammation of gastric mucosa triggers a pathway of chronic active gastritis, multifocal atrophy, IM, gastric dysplasia and finally invasive gastric adenocarcinoma ([Fig. 1](#f1-jcp-20-25){ref-type="fig"}).[@b15-jcp-20-25] The pathogenesis of intestinal type gastric cancer can be explained by a multistep process from chronic gastritis through AG, IM, and dysplasia to cancer. The presence of AG, which has been traditionally defined as the loss of glands,[@b16-jcp-20-25] is well known as a risk factor of gastric cancer. The risk of gastric cancer increases with greater extent and higher degree of gastric mucosal atrophy.[@b17-jcp-20-25] Gastric IM is defined as the replacement of the surface, foveolar, and glandular epithelium in the gastric mucosa by intestinal epithelium with the presence of Paneth cells, goblet cells and absorptive cells.[@b17-jcp-20-25] Several studies suggest that AG and IM are major precursor lesions of gastric cancer.[@b18-jcp-20-25]--[@b20-jcp-20-25] These relationships were observed before the identification of *H. pylori* infection in 1982.[@b21-jcp-20-25] Gastric cancer divides into 2 major histologic types, intestinal-type and diffuse-type, by Lauren classification.[@b22-jcp-20-25] The intestinal-type cancers are believed to arise secondary to AG and IM.[@b23-jcp-20-25] On the contrary, diffuse-type gastric cancer usually arises independently of IM. This raised doubts about the association between IM and gastric cancer development.[@b24-jcp-20-25] It is thought that diffuse type is more likely to have a primary genetic etiology, and the involvement of *H. pylori* is probably limited to a subset of sporadic cases.[@b23-jcp-20-25],[@b24-jcp-20-25] However, many studies suggest that both intestinal and diffuse types of gastric carcinoma are associated with *H. pylori* infection.[@b25-jcp-20-25],[@b26-jcp-20-25] Compared with other risk factors of gastric cancer, AG and IM increase the risk of intestinal type gastric cancer exponentially. The risk of gastric cancer in subjects with severe fundal AG was 5.76 times higher than that in those having little or no fundal AG.[@b27-jcp-20-25] In addition, the subjects with IM have more than a 10-fold increased risk of developing gastric cancer.[@b28-jcp-20-25] In addition, several groups have reported the correlation between *H. pylori* infection and gastric cancer. Moreover AG and IM, precursors of gastric cancer, elevate the risk of gastric cancer.[@b18-jcp-20-25],[@b19-jcp-20-25] In a prospective study of 1,526 subjects, 1,246 patients had *H. pylori* infection and 280 did not.[@b18-jcp-20-25] During mean follow-up of 7.8 years, gastric cancer developed in individuals (36 patients, 2.9%) infected with *H. pylori* but not in the uninfected persons.[@b18-jcp-20-25] Histological description of severe gastric atrophy, corpus-predominant gastritis, or IM are increasing risk factors of gastric cancer.[@b18-jcp-20-25] In addition, in a cohort of 4,655 healthy asymptomatic subjects, the risk of gastric cancer increased stepwise from chronic atrophic gastritis (CAG)-free gastritis \[*H. pylori*(+)/CAG (−) group\] (hazard ratio \[HR\], 7.13; 95% confidence interval \[CI\], 0.95 to 53.33) to CAG \[*H. pylori*(−)/CAG(+) group\] (HR, 14.85; 95% CI, 1.96 to 107.7) and finally to severe CAG with extensive IM \[*H. pylori*(−)/CAG(+) group\] (HR, 61.85; 95% CI 5.6 to 682.64) in which *H. pylori* is lost. So it is probable that *H. pylori* alone is not directly associated with gastric carcinogenesis,[@b19-jcp-20-25] but *H. pylori* -- induced chronic inflammation can provide the seed of cascade leading to gastric cancer, which can progress continuously even in the absence of *H. pylori*.[@b29-jcp-20-25] The patients with *H. pylori* infection and IM have more than 6.4-fold increased risk of gastric cancer than the subjects of infected with *H. pylori* infection but without IM.[@b18-jcp-20-25] In a cohort study of 2,224 subjects conducted in Republic of Korea, the group with IM have 10.9-fold increased risk of gastric cancer.[@b20-jcp-20-25] Therefore, each lesion of AG or IM will increase the incidence of gastric cancer, and if both lesions are combined, the incidence of gastric cancer will increase even more. As mentioned above, *H. pylori* infection triggers a multistep progression from chronic gastritis, gastric atrophy, IM and finally into gastric cancer.[@b30-jcp-20-25] *H. pylori* was identified in 1982 by Marshall and Warren.[@b31-jcp-20-25] *H. pylori* is a gram-negative, flagellated bacterium about 3 μm long with a diameter of about 0.5 μm.[@b31-jcp-20-25] *H. pylori* became the first bacterium to be classified as a type I carcinogen by International Agency for Research on Cancer (IARC) working group in 1994,[@b32-jcp-20-25] and now it is considered the most common etiologic bacterium of gastric cancer.[@b1-jcp-20-25] Evidences supporting that came out from several meta-analyses. In a meta-analysis of 19 cohort or case-control studies, the summary odds ratio for gastric cancer in *H. pylori*-infected subjects is 1.92 (95% CI, 1.32 to 2.78).[@b33-jcp-20-25] In another meta-analysis of 42 cohort or case-control studies, the summary odds ratio for *H. pylori* infection in relation to gastric carcinoma was 2.04 (95% CI, 1.69 to 2.45).[@b34-jcp-20-25] So, these studies show the clear association between *H. pylori* and gastric adenocarcinomas.[@b33-jcp-20-25],[@b34-jcp-20-25] However, among *H. pylori*-positive patients, only 1% to 2% subjects will develop gastric cancer,[@b17-jcp-20-25] suggesting that the final effects of *H. pylori* infection could be determined by prevalence, environmental factors, bacterial factors and host factors.[@b35-jcp-20-25] Despite the clear relationship between *H. pylori* infection and gastric adenocarcinomas through AG and IM, especially in intestinal-type of gastric cancer, the mechanisms of process about chronic inflammation and developing gastric cancer are under investigation. The enhanced production of free radicals by chronic *H. pylori* infection causes mutations in target cells so the neoplastic clones are established.[@b36-jcp-20-25] And tumor necrosis factor alpha from plays major roles in the growth, invasion and metastasis of neoplasm. This mechanism was called 'a perigenetic pathway'.[@b36-jcp-20-25] Another study suggested that the TNF-α inducing protein (Tipα) from *H. pylori* binds to and enters the nucleus through a specific biding molecule, act as a carcinogen of gastric cancer.[@b37-jcp-20-25]

PREVALENCE OF ATROPHIC GASTRITIS AND INTESTINAL METAPLASIA
==========================================================

A meta-analysis of 14 studies on incidence of AG was reported in 2010,[@b10-jcp-20-25] of which the incidence rates of AG ranged from 0% to 10.9% per year.[@b10-jcp-20-25] This wide range of incidence is explained by the particular settings in which the diagnosis of AG was made.[@b10-jcp-20-25] The lowest incidence rates (0%) were found in patients with reflux esophagitis and in patients successfully treated for *H. pylori* infection.[@b38-jcp-20-25],[@b39-jcp-20-25] The highest incidence rate (10.9%) was observed in a study conducted in patients who underwent vagotomy for ulcer disease.[@b40-jcp-20-25] Regarding the *H. pylori* infection, the CAG incidence rate was higher in *H. pylori*-positive patients than in *H. pylori*-negative ones.[@b10-jcp-20-25] In a meta-analysis, rate ratios comparing the incidence of AG in *H. pylori* positive patients to that in *H. pylori* negative ones ranged from 2.4 to 7.6 with a summary estimate of 5.0 (95% CI, 3.1 to 8.3).[@b10-jcp-20-25] In contrast, reports on the incidence of IM are rare in asymptomatic general population, because upper gastrointestinal endoscopy with histological examination is needed to estimate the the prevalence of IM. In a study about the relationship between IM and *H. pylori* infection in the Netherlands, IM was found more often in *H. pylori* positive patients than in *H. pylori* negative ones (33.9% vs. 15.2%, *P* \< 0.001).[@b41-jcp-20-25] The mean age of IM positive patients was 64 years and that of IM negative ones was 72 years (*P* \< 0.005).[@b41-jcp-20-25] In a Japanese prospective study with a follow-up of 7.8 years, IM was detected in as many as 37% of 1,426 *H. pylori* positive patients (mean age: 52.3 years) while in only 2% of 280 uninfected patients (mean age: 52.7 years).[@b18-jcp-20-25] There are several studies regarding prevalences of AG and IM in Republic of Korea. In a cohort study consisted of 389 subjects (≥ 16 years), prevalences of AG in the antrum and corpus were 42.5% and 20.1%, and prevalences of IM were 28.6% and 21.2%, respectively.[@b11-jcp-20-25] In another study reporting age-adjusted prevalence in Republic of Korea, the prevalence of AG was 42.7% for men and 38.1% for women (*P* = 0.194) and that of IM was 42.5% for men and 32.7% for women (*P* = 0.005).[@b42-jcp-20-25] The prevalence of AG and IM increases significantly with age for both men and women.[@b42-jcp-20-25] A multicenter study of Republic of Korea in 2006, with 25,536 asymptomatic subjects assigned, evaluated that the prevalences of endoscopic AG and IM were 27.1% and 7.1%, which were lower than those estimated with histologic diagnoses.[@b43-jcp-20-25] The proportions of AG and IM in patients aged 40 years or less were 14.9% and 2.7%, and in those aged 60 years or more were 43.5% and 12.3%. This study showed that the prevalence of AG and IM increased significantly with age and male.[@b43-jcp-20-25] The prevalences of endoscopic AG and IM were 40.7% and 12.5% in a multicenter study of 4,023 subjects in 2011, significantly higher than those of a multicenter study in 2006.[@b44-jcp-20-25] In addition, the prevalences of AG and IM in males were still higher than those in females.[@b44-jcp-20-25] This increase in prevalence of AG and IM may be attributed to aggressive diagnosis made by physicians in 2011 relative to 2006 rather than the real increase of prevalence rate of AG and IM.[@b44-jcp-20-25] The prevalence of AG and IM varies (9.4% to 63.8% in case of AG; 7.1% to 42.5% in case of IM) depending on diagnostic methods and countries ([Table 1](#t1-jcp-20-25){ref-type="table"}).[@b11-jcp-20-25],[@b42-jcp-20-25]--[@b50-jcp-20-25]

RISK FACTORS OF ATROPHIC GASTRITS AND INTESTINAL METAPLASIA
===========================================================

Several studies have investigated that dietary causes such as excessive salt intake, deficient ascorbic acid, and insufficient carotene could be risk factors of AG, IM, and gastric cancer.[@b15-jcp-20-25],[@b51-jcp-20-25] However, among the many risk factors, *H. pylori* infection is considered as the most important risk factor of AG and IM.[@b18-jcp-20-25]--[@b20-jcp-20-25],[@b32-jcp-20-25] Especially, bacterial virulence genes such as *cagA* and *VacA* were found to be important risk factors of AG, IM, and gastric cancer.[@b52-jcp-20-25]--[@b56-jcp-20-25] In a study of 58 subjects of *H. pylori* infection, with a mean follow-up period of 11.5 years, *cagA* was associated with a significantly increased risk of AG and IM (OR, 3.48; 95% CI, 1.02 to 12.18).[@b53-jcp-20-25] Infection with *cagA*-positive strains further increased the risk for gastric cancer by 1.64 (95% CI, 1.21 to 2.24) overall in a meta-analysis.[@b54-jcp-20-25] *cagA* proteins secreted by *H. pylori* translocate into cytoplasm of gastric mucosa cells via its type IV secretion system after *H. pylori* attachment. The *cagA* can interrupt signaling pathways by phosphorylation-dependent and independent mechanisms, leading to cytoskeletal change, motility, and abnormal proliferation in normal gastric epithelial cells.[@b35-jcp-20-25] *VacA* is another well-known virulence factor, s1 and m1 forms of *VacA* are more common in disease-associated *H. pylori* strains, and s1m1 genotype was related to gastric epithelial damage, AG and IM.[@b52-jcp-20-25],[@b55-jcp-20-25],[@b56-jcp-20-25] From a study of a total of 370 *H. pylori*-infected patients, a high association was observed between the presence of AG or IM and the prevalence of *VacA*s1, m1, *cagA* strains of *H. pylori* genotypes.[@b56-jcp-20-25] Presence of atrophy was associated with *VacA*s1 (OR, 46.9; 95% CI, 8.6 to 256.4), *VacA*m1 (OR, 10.1; 95% CI, 4.3 to 23.7), and *cagA* (OR, 11.2; 95% CI, 4.5 to 27.8). Similarly, presence of IM was associated with *VacA*s1 (OR, 14.9; 95% CI, 4.2 to 53.2), *VacA*m1 (OR, 6.8; 95% CI, 2.9 to 15.9), and *cagA* (OR, 4.8; 95% CI, 2.1 to 10.6).[@b56-jcp-20-25] Furthermore, other virulence factors such as *SabA* were also found and *SabA* (outer membrane protein) positive subjects is associated with AG, IM and gastric cancer.[@b57-jcp-20-25]

In a multicenter prospective study in Republic of Korea, risk factors of AG were *H. pylori* infection of antrum and corpus, *cagA* and *VacA*m1 positivity, age ≥ 61 years. The risk factors of IM were age ≥ 61 years, *H. pylori* infection, strong spicy food, a smoking history and the presence of *IL10*-592 C/A as against A/A.[@b11-jcp-20-25] In conclusion, virulence factor of *H. pylori* was the most important risk factor of AG, while environmental or host factor were more important risk factors for IM. In another study on the risk factors of endoscopic AG and IM, the risk factors for AG were male sex, age groups of 40 to 59 years and \> 60 years, positive *H. pylori* serology, IM, and education below the college level (OR; 5.00, 2.55, 1.38, 1.41, 4.29, and 1.35, respectively).[@b44-jcp-20-25] The risk factors for IM were male sex, AG, age groups of 40 to 59 years and \> 60 years, positive *H. pylori* serology, having relatives with gastric cancer, consumption of dairy products and education below the college level (OR; 3.25, 2.17, 3.16, 1.88, 3.68, 1.48, 1.40, and 1.47, respectively).[@b44-jcp-20-25]

Many studies show that the *VacA* and *cagA* genotypes of *H. pylori* are not equally distributed over the world.[@b58-jcp-20-25]--[@b60-jcp-20-25] There are significant differences in *H. pylori* genotypes between populations from Asia, different parts of Europe, and North and South America. Given the geographic distribution of specific *H. pylori* genotypes, it could be speculated that there might be differences in incidence of gastric cancer.[@b58-jcp-20-25]--[@b60-jcp-20-25]

CLASSIFICATION OF GASTRITIS AND INTESTINAL METAPLASIA
=====================================================

There is no universally accepted classification of gastritis, although several classifications of gastritis have been proposed. The first classification based on histopathological examination of gastric mucosa collected by so-called blind biopsies and samples collected during surgical procedures was created by Schindler.[@b61-jcp-20-25] Schindler[@b61-jcp-20-25] described that gastritis was divided into a superficial gastritis ([Fig. 2B](#f2-jcp-20-25){ref-type="fig"}) that may progress to AG ([Fig. 2C](#f2-jcp-20-25){ref-type="fig"}) and IM ([Fig. 2D](#f2-jcp-20-25){ref-type="fig"}) with time, which is different from normal ([Fig. 2A](#f2-jcp-20-25){ref-type="fig"}). Additionally, Schindler[@b61-jcp-20-25] proposed that there were different courses and prognoses of disease by the type of the gastritis. And a novel classification and grading of gastritis was devised by a group of experts at the 9th World Congress of Gastroenterology in Sydney, Australia in 1990.[@b62-jcp-20-25] The histological division of Sydney System is a practical guideline upon which the morphological features of gastritis in endoscopic biopsy samples should be documented. Type, severity and extent of gastric inflammation composed to possible etiology should be detailed depending on the chart. The Sydney System asserted the routine gastric biopsy sampling protocol (two from antrum and two from corpus, both from anterior and posterior walls) and sample fixation in adequately labelled separate containers.[@b62-jcp-20-25] Now the updated Sydney system in 1996 is most widely used as the classification of gastritis.[@b63-jcp-20-25] The original Sydney classification of gastritis dividing into gastritis acute, chronic and special forms, and grading of chronic inflammation, neutrophil activity, atrophy, IM and *H. pylori* density into mild, moderate and marked categories were kept.[@b62-jcp-20-25] The updated Sydney system introduced a visual analogue scale for evaluating the severity of histological grading ([Fig. 3](#f3-jcp-20-25){ref-type="fig"}).[@b63-jcp-20-25] The histological features of the gastric mucosa were recorded using updated Sydney system scores, that is, 0 = none, 1 = mild, 2 = moderate, and 3 = marked.[@b63-jcp-20-25] It changed the routine of endoscopic biopsy sampling by the introduction of biopsy sampling from the incisura angularis and modified corpus and antrum biopsy locations from the two opposite walls in lesser and greater curvature of both parts ([Fig. 4](#f4-jcp-20-25){ref-type="fig"}).[@b63-jcp-20-25] Endoscopic description of acute gastritis by Sydney system are divided into edema, exudates, erosions and hemorrhage. In contrast, endoscopic diagnosis and classification of chronic gastritis are reliable depending on the inter-observer.[@b63-jcp-20-25]

The updated Sydney system is the most widely used classification of gastritis. However, it does not reflect prognosis of gastric cancer risk in subjects with CAG. Therefore, the Operative Link on Gastritis Assessment (OLGA) was developed to improve the histological staging system for gastric atrophy.[@b64-jcp-20-25] OLGA system uses gastric biopsy sampling protocol defined by Sydney System and the histological grading system recommended by the updated Sydney System ([Fig. 5](#f5-jcp-20-25){ref-type="fig"}).[@b64-jcp-20-25] Long-term follow-up studies with follow-up ranges from 144 to 204 months proved that the OLGA staging reflects relevant information on clinic-pathological outcome of gastritis and therefore *H. pylori* negative patients with low OLGA stages could be excluded from secondary preventive surveillance of gastric cancer.[@b65-jcp-20-25] Whereas patients with higher OLGA stages (Stages III and IV) should be considered definitely candidates for endoscopic examination.[@b65-jcp-20-25] However, there are no universally acceptable classification methods for gastritis, yet. For the optimization of the methods to interpret the gastritis, repetitive communication between the endoscopists and pathologists should be required.

IM could be classified according to the phenotype of mucin. Type I IM expresses only sialomucins, type III expresses sulfomucins and type II expresses a mixture of gastric and intestinal mucins.[@b66-jcp-20-25] Several studies reported that type III or incomplete IM increase the risk of gastric cancer.[@b67-jcp-20-25],[@b68-jcp-20-25] However, a contrary result has been published.[@b69-jcp-20-25] Furthermore, IM subtyping was not found to play a major role in the prediction of gastric cancer development in Republic of Korea.[@b70-jcp-20-25] At the present time subtyping of IM is not recommended for clinical practice.[@b71-jcp-20-25] However, a recent systemic review concluded that the incomplete IM was significantly related to the prevalence of gastric cancer. Moreover, it reported that the relative risks of gastric cancer were from 4- to 11-fold higher for the presence of incomplete type in comparison to complete type or in comparison to the absence of incomplete type. This systemic report concluded that subtyping of IM have the scientific evidence on the evaluation of gastric cancer risk.[@b72-jcp-20-25]

DIAGNOSIS OF ATROPHIC GASTRITIS AND INTESTINAL METAPLASIA
=========================================================

In most of previous studies about the clinical relevance of endoscopic and histologic diagnosis of the gastritis, the diagnosis of gastritis should have been based on histological examination of the gastric mucosa.[@b73-jcp-20-25],[@b74-jcp-20-25] Especially in the young age group, a high index of suspicion of gastric atrophy is important, and confirmation of the diagnosis by histology is necessary.[@b75-jcp-20-25] However in another study, endoscopic and histological diagnosis displayed high correlation.[@b76-jcp-20-25] Particularly, the benefits of upper endoscopy to conform atrophic change of gastric mucosa are generally acceptied.[@b77-jcp-20-25],[@b78-jcp-20-25] Endoscopic features of AG is the visibility of a vascular pattern of gastric mucosa ([Fig. 2C](#f2-jcp-20-25){ref-type="fig"}) than normal gastric mucosa ([Fig. 2A](#f2-jcp-20-25){ref-type="fig"}). Gastric IM ([Fig. 2D](#f2-jcp-20-25){ref-type="fig"}) is defined as the replacement of the surface, foveolar, and glandular epithelium in the oxyntic or antral mucosa by intestinal epithelium. The endoscopic finding of IM is observed as a mucosal nodular pattern, usually occuring after the occurrence of the AG. It is not difficult to diagnose severe cases of AG and IM properly by endoscopic findings, but it is difficult to make the diagnoses of mild AG and IM.[@b75-jcp-20-25] Sometimes endoscopic diagnosis is not correlated to histological diagnosis. Therefore, it is proper to biopsy in suspected cases of AG and IM. However, atrophic mucosal changes are not distributed similarly in whole gastric mucosa. So multiple endoscopic biopsy of gastric mucosa does not always represent AG. Furthermore, it is difficult to take multiple biopsies of all subjects with simple gastritis.[@b79-jcp-20-25],[@b80-jcp-20-25] To resolve this clinical difficulty, noninvasive tests for precursor lesions such as serum level of pepsinogen (PG), gastrin-17 and *H. pylori* immunoglobulin G antibodies could be used as biomarkers of AG and IM to replace endoscopic biopsy.[@b81-jcp-20-25] In the review, we discuss about three diagnostic methods for AG and IM; endoscopic, histological and PG I/II ratio.

1.. Endoscopic diagnosis of atrophic gastritis and intestinal metaplasia
------------------------------------------------------------------------

Endoscopic diagnosis of AG and IM is the basic method. However, there is the possibility of low sensitivity, specificity and inter-observer variation. Endoscopic diagnosis of AG is made when the visibility of a vascular pattern followed by loss of gastric mucosal gland is present ([Fig. 2C](#f2-jcp-20-25){ref-type="fig"}). There are various criteria to endoscopic classification of atrophic gastritis. AG due to *H. pylori* infection is more common in the east and atrophic mucosal change progresses from antrum to the corpus along with lesser curvature ([Fig. 6C](#f6-jcp-20-25){ref-type="fig"}), this endoscopic features reflect Kimura-Takemoto classification well.[@b82-jcp-20-25] The boundaries of the mucosal atrophy is called the F line ([Fig. 6B](#f6-jcp-20-25){ref-type="fig"}), and AG is classified into six types. The closed-type AG indicates that the atrophic border remains on the lesser curvature, while the open-type AG means that the atrophic border no longer exists on the lesser curvature but extends along the anterior and posterior walls of the stomach ([Fig. 6A](#f6-jcp-20-25){ref-type="fig"}). However, Western physicians lack a good understanding of Kimura-Takemoto classification because the ratio of auto-immune gastritis is greater in the West than in the East and *H. pylori* infection rate is rather low.[@b83-jcp-20-25] In addition, the inter-observer reliability is rather low in Kimura-Takemoto classification from endoscopic features. Other limitation of the endoscopic diagnosis of AG and IM is the lower sensitivity and specificity than the pathological diagnosis. In the study of 1,333 subjects in Republic of Korea, the sensitivity of the prevalence of endoscopic diagnosis of atrophy was significantly low in age below 50 years old.[@b75-jcp-20-25] The sensitivity and specificity of endoscopy for the diagnosis of gastric atrophy based on histological findings were 61.5% and 57.7% in the antrum, and were 46.8% and 76.4% in the corpus of the stomach. Especially endoscopic diagnosis of AG was inaccurate below 50 years of age because of mild atrophic mucosal change may look normal in endoscopy.[@b75-jcp-20-25] In addition, the sensitivity and specificity of endoscopic IM diagnosis were also low in study by Lim et al.[@b84-jcp-20-25] The sensitivity and specificity of endoscopic diagnosis of IM based on histology were 24.0% and 91.9% for the antrum and were 24.2% and 88.0% for the corpus. As indicated by a multivariate analysis, the activity of mucosal inflammation and the presence of endoscopic AG were associated with the sensitivity of endoscopic diagnosis of IM in the antrum, while benign gastric ulcers, dysplasia, and the presence of endoscopic AG were associated with the sensitivity of endoscopic diagnosis of IM in the corpus.[@b84-jcp-20-25] Thus, a high level of suspicion is important to increase the sensitivity of endoscopic diagnoses of IM, especially when adenoma, endoscopic AG and ulcer are present, and confirmation of the doubt by histological diagnosis is necessary.

Other methods for endoscopic diagnosis of AG or IM are magnification chromoendoscopy and narrow band imaging (NBI). Several studies have suggested that chromoendoscopy with magnification could help to identify lesions of IM and dysplasia.[@b85-jcp-20-25] However, high resolution magnifying endoscopy without chromoendoscopy also appears superior to standard endoscopy, allowing great accuracy for the diagnosis of *H. pylori* gastritis, IM, and dysplasia.[@b86-jcp-20-25],[@b87-jcp-20-25] The recent technology of NBI has been found to have good sensitivity and specificity for the diagnosis of gastric precancerous lesions.[@b88-jcp-20-25],[@b89-jcp-20-25] However, there is no agreement on which NBI patterns are associated with gastric precancerous lesions. So, further study is needed to apply NBI in diagnosis of AG and IM.

2.. Histological diagnosis of atrophic gastritis and intestinal metaplasia
--------------------------------------------------------------------------

The second method of diagnosis of AG is histopathology. The updated Sydney system is the most widely accepted for classification and grading of gastritis. The updated Sydney system recommended five biopsies, two from the antrum, one from the incisura, and two from the corpus, because atrophic mucosal change and IM of gastric mucosa progress from antrum to body ([Fig. 3](#f3-jcp-20-25){ref-type="fig"}).[@b63-jcp-20-25] If it is difficult to obtain at these three points, biopsies from antrum and corpus are recommended. It is desirable to examine specimens from antrum and corpus of lesser and greater curvature, yet there are practical difficulties. Clinically, one biopsy specimen from lesser curvature and the other from greater curvature are used to evaluate AG and IM.[@b73-jcp-20-25],[@b84-jcp-20-25],[@b90-jcp-20-25]

Histological diagnosis is difficult when the specimens are inadequate. Deep portion of normal gastric mucosa are composed of different types of cells in antrum and body. Normal gastric mucosa of the antrum is composed of mucous glands which secrete gastric mucus, and that of the body is composed of parietal cell and chief cell which secrete gastric acid and digestive enzymes. Sometimes severe inflammation obscures the gland's population, making it impossible to assess mucosal atrophy reliably. Such cases can be labeled as 'indefinite for atrophy' and the final judgment can be deferred until the inflammation has regressed. In addition, the diagnosis of 'indefinite for atrophy' may be controversial among pathologists due to the difficulty in histological diagnosis.[@b91-jcp-20-25] IM is defined as the replacement of the surface, foveolar, and glandular epithelium in the oxyntic or antral mucosa by intestinal epithelium. These IM has been subtyped by classification of mucin expression. There are several classification systems for IM. The most widely used and useful classification is was made by Jass and Filipe[@b92-jcp-20-25] in 1981. Type I IM (complete) is positive for the sialomucin, and type II IM (incomplete) is positive for sialomucin in goblet and columnar cell. While, type III IM (imcomplete) is positive for sulphomucin.[@b92-jcp-20-25] Complete type IM is similar to small intestine in pathologic features and tests positive for the MUC2 secreted by goblet cells. While, incomplete type IM is similar to large intestine in pathologic features, and positive for MUC5AC, MUC6 secreted by gastric mucosa and MUC2.[@b70-jcp-20-25],[@b93-jcp-20-25] In addition, high iron diaminealcian blue (HID-AB) stain can help classify the types of IM. Type I IM expresses only sialomucins (bright blue) ([Fig. 7; type I](#f7-jcp-20-25){ref-type="fig"}) and type II, III expresses sialomucins (bright blue) and sulfomucins (black) ([Fig. 7; type II and type III](#f7-jcp-20-25){ref-type="fig"}).[@b70-jcp-20-25] Jass and Filipe[@b92-jcp-20-25] reported that type III IM is associated with intestinal type gastric cancer. Other researchers have suggested that incomplete type IM is associated with gastric cancer. As such, it is still controversial discussing which type of IM is related with gastric carcinogenesis.[@b67-jcp-20-25],[@b68-jcp-20-25],[@b70-jcp-20-25] In a cohort study of 861 subjects conducted in Republic of Korea, type III IM was associated with aging (*P* = 0.036), and type II IM was associated with gastric carcinogenesis in the presence of *H. pylori* infection (*P* \< 0.05).[@b70-jcp-20-25]

3.. Diagnosis by serum pepsinogen I/II ratio
--------------------------------------------

The third diagnostic method of AG or IM is a measurement of serum PG I, II and I/II ratio. The radioimmunoassay method is used to measure serum PG levels. Recently, a new method has emerged to measure PG level.[@b94-jcp-20-25],[@b95-jcp-20-25] The present methods to measure PG level are Latex-enhanced Turbidimetric Immunoassay (HBi Corp., Seoul, Korea; imported from Shima Laboratories, Tokyo, Japan),[@b90-jcp-20-25],[@b94-jcp-20-25],[@b95-jcp-20-25] and enzyme-linked immunosorbent assays (Biohit ELISA kit; Biohit, Helsinki, Finland).[@b96-jcp-20-25],[@b97-jcp-20-25] PG has been used to screen AG, IM and gastric adenocarcinoma for more than 20 years because of its non-invasiveness and cost-effectiveness. In Japan, PG screening for gastric cancer has been used to improve population compliance.[@b98-jcp-20-25] However, PG screening is not accepted as a generalized screening method of AG or IM worldwide because of low positive predictive value in other countries.[@b99-jcp-20-25]

PG I is produced by chief cells in antrum and corpus, while PG II is produced by the chief cells and mucous neck cells of the whole gastric mucosa. When gastric atrophy develops, chief cells are replaced by pyloric glands, leading to a decrease in PG I level, while PG II levels is relatively unaffected, so a low PG I/II ratio reflect the severity of AG.[@b100-jcp-20-25],[@b101-jcp-20-25] In a prospective study of 5,113 subjects in Japan, screening for gastric cancer with PG I \< 70 ng/mL and PG I/II ratio \< 3 as the cut-off points had the sensitivity and specificity of 84.6% and 73.5%, respectively.[@b102-jcp-20-25] Generally PG I/II ratio 3.0 or less has been widely accepted as a cut-off value in several studies.[@b103-jcp-20-25] However, in a recent Korean study which evaluated the relationship between PG level and AG, a new cut-off value of PG I/II ratio, 3.2, was suggested to diagnose AG.[@b90-jcp-20-25] The study suggested that serum PG I/II ratio remarkably decreased in correlation with the extent of atrophy by the Kimura-Takemoto classification.[@b90-jcp-20-25] In another Korean research, PG I and PG II were negatively correlated with AG and only PG I/II ratio was positively correlated with AG.[@b95-jcp-20-25] Serum PG I and PG II were higher in *H. pylori*-positive than in *H. pylori*-negative subjects, because a growth rate of PG II was higher than that of PG I in *H. pylori* positive individuals.[@b90-jcp-20-25],[@b94-jcp-20-25],[@b95-jcp-20-25]

Moreover, a significantly positive correlation was found between age and the PG II (*P* \< 0.001) and a negative correlation between age and the PG I/II ratio (*P* \< 0.001). No correlation was found between age and the PG I. Men had significantly higher PG I levels compared with women (*P* \< 0.001), and had a slightly higher PG II levels without statistical significance. These results suggest that the difference in the PG I levels observed between sex could be related to hormonal effects.[@b95-jcp-20-25] Consequently these results show that multiple factors could change the serum PG level. Thus, the proper cut-off value of PG level would be necessary in order to increase sensitivity and specificity.[@b90-jcp-20-25]

MANAGEMENT STRATEGY FOR ATROPHIC GASTRITIS AND INTESTINAL METAPLASIA
====================================================================

Up to the present time, there are no unified clinical guidelines for prevention of gastric cancer regarding the classification of high-risk groups progressing to gastric cancer.[@b104-jcp-20-25] However, through many studies, AG and IM are considered as precancerous lesions. Prevention and treatment of AG and IG could decrease the prevalence of gastric cancer. AG and IM could be managed by several strategies. *H. pylori* infection triggers a multistep progression from chronic gastritis, AG, IM and finally to invasive gastric cancer.[@b30-jcp-20-25] To reduce the prevalence of gastric cancer, *H. pylori* eradication is a key step in management strategy. Another strategy is the surveillance to detect EGC in the subjects with AG or IM, with additional managements of several risk factors of AG and IM.

1.. *Helicobacter pylori* eradication
-------------------------------------

*H. pylori* eradication is the basis of the treatment of AG and IM. However, it is still a controversial topic with a question if *H. pylori* eradication can improve gastric mucosa of AG and IM ([Table 2](#t2-jcp-20-25){ref-type="table"}).[@b105-jcp-20-25]--[@b119-jcp-20-25] Several meta-analyses on correlation of *H. pylori* eradication and histologic improvement of AG and IM were reported in 2007, 2011 and 2014.[@b7-jcp-20-25]--[@b9-jcp-20-25] A meta-analysis of 8 articles in 2007, described that AG of antrum and corpus improved, but IM did not improve.[@b7-jcp-20-25] Another meta-analysis of 12 articles in 2012 reported that AG of corpus improved, but AG and IM of antrum did not improve.[@b8-jcp-20-25] *H. pylori* eradication proved histological improvement of gastric mucosa in AG but no reversal of IM has been shown. Thus, IM was considered as a 'point of no return'.[@b7-jcp-20-25],[@b8-jcp-20-25] In contrast, a recent meta-analysis suggests that there were improvements in IM after *H. pylori* eradication.[@b9-jcp-20-25] Meta-analysis of 16 articles in 2014, described that AG of antrum and corpus improved, IM of antrum improved but IM of corpus did not improve.[@b9-jcp-20-25] At present, guidelines in Asia (China, Japan, and Korea) recommend *H. pylori* eradication in subjects with AG and IM.[@b120-jcp-20-25]--[@b122-jcp-20-25] However, a study to prevent gastric cancer in Japan suggests that appropriate treatment time of *H. pylori* is younger age before the development of AG or IM.[@b123-jcp-20-25] Because *H. pylori* eradication decreased the prevalence of gastric cancer only in patients without premalignant lesions like AG and IM.[@b18-jcp-20-25],[@b124-jcp-20-25] Similarly in a Korean cohort study, the incidence of gastric cancer was 10.9 times higher in the subjects with IM, and the eradication of *H. pylori* could not reduce gastric cancer development in patients with IM.[@b20-jcp-20-25] So, the diagnosis and treatment of *H. pylori* infection in younger people before the development of AG and IM could be more effective strategy to prevent gastric cancer. Considering the positive results of the recent studies showing improvement of AG and IM by *H. pylori* eradication, it is expected to reduce the occurrence of gastric cancer.[@b9-jcp-20-25] Therefore, further prospective studies are needed to determine the optimal strategy about *H. pylori* eradication to prevent gastric cancer.

2.. Screening for early detection of gastric cancer
---------------------------------------------------

The 5-year survival rate of EGC was greater than 90%.[@b125-jcp-20-25] Moreover, surgery is no longer needed because of the recent advances in endoscopic resection techniques and technologies for EGC.[@b126-jcp-20-25] Therefore, it is important to establish optimal screening methods in high gastric cancer prevalence area such as Republic of Korea and Japan. Republic of Korea and Japan have been conducting biennial screening of gastric cancer in general population over 40-years-of-age.[@b127-jcp-20-25],[@b128-jcp-20-25] However, optimal screening interval of gastric cancer is still under discussion. In a Japanese study, the 5-year survival rate was significantly higher in subjects who had undergone endoscopic examinations within 2 years before being diagnosed with gastric cancer than that of patients who had not (96.5% vs. 71.0%; *P* \< 0.01).[@b129-jcp-20-25] However, the survival rates for a group of 1-year screening interval and a group of 2-year were not significantly different (*P* = 0.4595).[@b129-jcp-20-25] These results have served as the basis for recommending that the optimal interval for screening of gastric cancer should be 2 years. Yet, optimal screening methods in high risk group of gastric cancer are still controversial. A recent Korean study in a subgroup of subjects with severe IM, EGC was more frequently observed in the 1-year interval screening group than the 2-year interval screening group (66.7% vs. 35.5%; *P* = 0.047).[@b130-jcp-20-25] Another Korean study conducted with the general population in a healthcare center reported that the proportion of EGC was higher in an annual screening group than in a biennial screening group (98.6% vs. 80.7%; *P* \< 0.01) and endoscopic resection was performed more frequently in the annual screening group (56.9% vs. 33.3%; *P* = 0.02).[@b131-jcp-20-25] This result also suggested that 1-year interval surveillance could be useful for high risk subjects with IM.

3.. Control of other risk factors
---------------------------------

Adequate consumption of vegetables and fruits seems to reduce the risk of cancer and decrease the incidence of gastric cancer in the West. Although some studies for premalignant gastric lesions have shown positive results of vitamin C, folic acid, and beta-carotene supplementation, though these results were not confirmed in a large meta-analysis.[@b132-jcp-20-25]--[@b135-jcp-20-25] *H. pylori* eradication is the main strategy for prevention of gastric cancer in individuals with AG and IM, but it may be helpful to change diet and supply vitamin C, folic acid, and beta-carotene. Consequently, further large cohort study is needed to establish the optimal strategy of gastric cancer prevention.

CONCLUSION
==========

Gastric cancer is still a major cause of death in Republic of Korea. To reduce the prevalence of gastric cancer, it is very important to classify and manage the high risk groups of gastric cancer. Furthermore, *H. pylori* infection triggers a multistep inflammation from chronic gastritis, atrophic gastritis, IM and finally to gastric cancer. Many studies have proved that AG and IM are precancerous lesions of gastric cancer. Diagnostic methods of AG and IM are endoscopic, histological findings and PG I/II ratio. Each method has advantages and disadvantages, and it is necessary to select the proper test according to the individual cases. As the infection of *H. pylori* is the most important risk factor of AG and IM it is important to perform *H. pylori* eradication to prevent the progression to gastric cancer. The appropriate time to prevent gastric cancer by *H. pylori* eradication is still under discussion. However, the most effective time point is before development of AG and IM. And it is difficult to know who will develop the AG and/or IM in the presence of *H. pylori*. *H. pylori* eradication had been known to improve AG histologically but not IM. However, a recent meta-analysis of IM after eradication of *H. pylori* reported the histological improvements even in cases of IM. In terms of early detection of gastric cancer 1-year interval of endoscopic screening for AG and IM could be superior in decreasing the prevalence of gastric cancer. Controlling other risk factors such as diet, vitamin C, beta-carotene and folic acid may be useful to decrease the prevalence of gastric cancer. However, further researches about the effect of *H. pylori* eradication, optimal screening interval and diet change, and various chemo-prevention trials to prevent the development of gastric cancer are needed.
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![Correa's theory regarding human gastric carcinogenesis: a multistep and multifactorial process. Gastritis begins from superficial gastritis and progresses into atrophic gastritis, metaplasia, dysplasia and gastric cancer. Adapted from Correa et al.[@b15-jcp-20-25]](jcp-20-25f1){#f1-jcp-20-25}

![Classificataion of gastritis (H&E, ×400). (A) Normal, (B) superficial gastritis, (C) atrophic gastritis, (D) intestinal metaplasia. Adapted from Schindler.[@b61-jcp-20-25]](jcp-20-25f2){#f2-jcp-20-25}

![Grading of gastritis by Sydney System: acute inflammation, chronic inflammation, atrophic gastritis, intestinal metaplasia, and *Helicobacter pylori* densitiy. Adapted from Dixon et al.[@b63-jcp-20-25]](jcp-20-25f3){#f3-jcp-20-25}

![The optimal gastric biopsy sites recommend by updated Sydney system. Biopsy specimens are taken at five different sites. A, lesser curvature of the antrum; B, greater curvature of the antrum; C, lesser curvature of the corpus; D, greater curvature of the corpus; and E, incisura angularis. Adapted from Dixon et al.[@b63-jcp-20-25]](jcp-20-25f4){#f4-jcp-20-25}

![Gastritis staging: the OLGA system. Atrophy is defined as loss of appropriate glands (with or without metaplasia). In each compartment, atrophy is scored in a four-tiered scale (0--3) according to the visual analogue scale of the updated Sydney system. Adapted from Rugge et al.[@b64-jcp-20-25]](jcp-20-25f5){#f5-jcp-20-25}

![Kimura-Takemoto classification of chronic atrophic gastirits: (A) Atrophic gastritis (AG) is classified into six types. The closed-type AG indicates that the atrophic border remains on the lesser curvature of the stomach, while the open-type AG means that the atrophic border no longer exits on the lesser curvature but extends along the anterior and posterior walls of the stomach, (B) the boundaries of the mucosal atrophy is called the F line, (C) progression of atrophic mucosal change from antrum to the corpus along with lesser curvature. Adapted from Kimura and Takemoto.[@b77-jcp-20-25]](jcp-20-25f6){#f6-jcp-20-25}

![Phenotype of intestinal metaplasia (IM) classifying by mucin: type I IM expresses only sialomucins (bright blue) and type II, III expresses sialomucins (bright blue) and sulfomucins (black) (High iron diamine and alcian blue \[pH 2.5\] \[HID-AB2.5\] staining, ×400). Adapted from Kang et al.[@b70-jcp-20-25]](jcp-20-25f7){#f7-jcp-20-25}

###### 

The prevalence of AG and IM in the world

  Author (year)                             Country   Diagnostic methods                                    Study population (n)   AG (%) antrum/body                                IM (%) antrum/body
  ----------------------------------------- --------- ----------------------------------------------------- ---------------------- ------------------------------------------------- -------------------------------------------------
  Kim et al. (2008)[@b11-jcp-20-25]         Korea     Histology                                             389                    42.5/20.1                                         28.6/21.2
  Kim et al. (2008)[@b42-jcp-20-25]         Korea     Histology                                             713                    42.7/38.1                                         42.5/32.7
  Park et al. (2012)[@b43-jcp-20-25]        Korea     Endoscopy                                             25,536                 27.1[^b^](#tfn3-jcp-20-25){ref-type="table-fn"}   7.1[^b^](#tfn3-jcp-20-25){ref-type="table-fn"}
  Joo et al. (2013)[@b44-jcp-20-25]         Korea     Endoscopy                                             4,023                  40.7[^b^](#tfn3-jcp-20-25){ref-type="table-fn"}   12.5[^b^](#tfn3-jcp-20-25){ref-type="table-fn"}
  Weck et al. (2007)[@b45-jcp-20-25]        Germany   Serology[^a^](#tfn2-jcp-20-25){ref-type="table-fn"}   9,444                  6.0[^b^](#tfn3-jcp-20-25){ref-type="table-fn"}    \-
  Borch et al. (2000)[@b46-jcp-20-25]       Sweden    Histology                                             501                    9.4[^b^](#tfn3-jcp-20-25){ref-type="table-fn"}    \-
  Asaka et al. (2001)[@b47-jcp-20-25]       Japan     Histology                                             2,455                  55.5[^b^](#tfn3-jcp-20-25){ref-type="table-fn"}   24.2[^b^](#tfn3-jcp-20-25){ref-type="table-fn"}
  Zou et al. (2011)[@b48-jcp-20-25]         China     Histology                                             1,022                  63.8[^b^](#tfn3-jcp-20-25){ref-type="table-fn"}   \-
  Eriksson et al. (2008)[@b49-jcp-20-25]    Finland   Histology                                             505                    \-                                                18.8/7.1
  Almouradi et al. (2013)[@b50-jcp-20-25]   USA       Histology                                             437                    \-                                                15.0[^b^](#tfn3-jcp-20-25){ref-type="table-fn"}

AG, atrophic gastritis; IM, intestinal metaplasia.

Serology was test by *Helicobacter pylori* immunoglobulin G antibodies.

Prevalence of AG or IM in the antrum and/or body.

###### 

Histological parameters of AG and IM after *Helicobacter pylori* eradication

  Author (year)                             Country    Study arms (n)   Follow-up (mo)   Histologic parameters                     
  ----------------------------------------- ---------- ---------------- ---------------- ----------------------- ----- ----- ----- -----
  Sung et al. (2000)[@b105-jcp-20-25]       China      226              245              12                      Yes   Yes   Yes   Yes
  Kim et al. (2000)[@b106-jcp-20-25]        Korea      41               16               24                      No    No    Yes   Yes
  Annibale et al. (2000)[@b107-jcp-20-25]   Italy      5                7                6                       Yes   Yes   Yes   Yes
  Ohkusa et al. (2001)[@b108-jcp-20-25]     Japan      115              48               12--15                  Yes   Yes   Yes   Yes
  Ruiz et al. (2001)[@b109-jcp-20-25]       Colombia   29               21               72                      Yes   No    No    No
  Ito et al. (2002)[@b110-jcp-20-25]        Japan      22               22               60                      Yes   Yes   Yes   Yes
  Annibale et al. (2002)[@b111-jcp-20-25]   Italy      40               0                6--12                   Yes   Yes   Yes   Yes
  Yamada et al. (2003)[@b112-jcp-20-25]     Japan      87               29               10--50                  Yes   Yes   Yes   Yes
  Iacopini at al. (2003)[@b113-jcp-20-25]   Italy      10               0                12                      Yes   No    Yes   No
  Kamada et al. (2003)[@b114-jcp-20-25]     Japan      37               8                36                      Yes   No    No    No
  Wambura et al. (2004)[@b115-jcp-20-25]    Japan      107              118              12                      Yes   Yes   Yes   Yes
  Lahner et al. (2005)[@b116-jcp-20-25]     Italy      38               36               48--137                 Yes   Yes   Yes   Yes
  Lu et al. (2005)[@b117-jcp-20-25]         China      92               87               36                      Yes   Yes   Yes   Yes
  Kamada et al. (2005)[@b118-jcp-20-25]     Japan      1,787            233              12                      Yes   Yes   Yes   Yes
  Toyokawa et al. (2010)[@b119-jcp-20-25]   Japan      241              19               60                      Yes   Yes   Yes   Yes

AG, atrophic gastritis; IM, intestinal metaplasia.
